Q2Pharma specializes in developing small-molecule drugs to be used in conjunction with commonly used antibiotics or as standalone medications against multi-drug-resistant (MDR) bacteria.

The company's lead compound, F19, has shown promise in combating deadly MDR bacterial infections. Whereas antibiotics kill the bacteria, antivirulent F19 inhibits bacterial toxin release, allowing the immune system to do its job more effectively, resolving the infection.

F19 has been shown to potentiate antibiotic efficacy, even for antibiotics to which the pathogen is otherwise resistant. Recent experiments have demonstrated F19's potent effects on several of the most common and deadly MDR bacteria.

Q2Pharma's platform technology is exclusively licensed from Case Western Reserve University in the United States, where Q2Pharma CSO and cofounder Professor Menachem Shoham is an associate professor.